Early research (Phase 1)Ended earlyNCT03429101What this trial is testingPoziotinib in Combination With T-DM1 in HER2-Positive Breast CancerWho this might be right forBreast Cancer Spectrum Pharmaceuticals, Inc 6
Testing effectiveness (Phase 2)Study completedNCT00934856What this trial is testingTrastuzumab Emtansine (T-DM1) in Combination With Docetaxel, and Potentially Pertuzumab, in Participants With Advanced Breast CancerWho this might be right forBreast Cancer Hoffmann-La Roche 98
Large-scale testing (Phase 3)Ended earlyNCT01641939What this trial is testingTrastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric CancerWho this might be right forGastric Cancer Hoffmann-La Roche 415
Early research (Phase 1)Study completedNCT03032107What this trial is testingPembrolizumab In Combination With Trastuzumab-DM1Who this might be right forBreast Cancer Dana-Farber Cancer Institute 20
Large-scale testing (Phase 3)Study completedNCT01702571What this trial is testingTrastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based TreatmentWho this might be right forBreast Cancer Hoffmann-La Roche 2,185
Large-scale testing (Phase 3)Study completedNCT01421992What this trial is testingMethylphenidate in Myotonic Dystrophy Type 1Who this might be right forDystrophia Myotonica 1 Laval University 28
Testing effectiveness (Phase 2)Ended earlyNCT03784599What this trial is testingT-DM1 and Osimertinib Combination Treatment to Target HER2 Bypass Track Resistance in EGFR Mutation Positive NSCLCWho this might be right forCarcinoma, Non-Small-Cell Lung The Netherlands Cancer Institute 28
Not applicableLooking for participantsNCT04003363What this trial is testingThe United Kingdom National Registry for Myotonic DystrophyWho this might be right forMyotonic Dystrophy Newcastle University 900
Not applicableUnknownNCT05231863What this trial is testingTyrosine Kinase Inhibitors (TKIs) in Trastuzumab Emtansine (T-DM1) Resistant HER2-positive Metastatic Breast Cancer: A Real-world StudyWho this might be right forBreast Cancer The First Affiliated Hospital with Nanjing Medical University 100
Large-scale testing (Phase 3)Enrolling By InvitationNCT06549400What this trial is testingAn Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Once Daily Mexiletine PR in Patients With Myotonic Dystrophy Type 1 and Type 2 Who Have Completed MEX-DM-302 Study.Who this might be right forMyotonic Dystrophy Lupin Ltd. 176
Large-scale testing (Phase 3)Looking for participantsNCT07486934What this trial is testingEfficacy, Safety, and Tolerability of Zeleciment Basivarsen (DYNE-101) in Participants With Myotonic Dystrophy Type 1Who this might be right forMyotonic Dystrophy Type 1 (DM1)DM1Myotonic Dystrophy+2 more Dyne Therapeutics 150
Testing effectiveness (Phase 2)Study completedNCT01406873What this trial is testingClinical Efficacy Trial of Mexiletine for Myotonic Dystrophy Type 1Who this might be right forMyotonic Dystrophy University of Rochester 42
Not applicableStudy completedNCT05400629What this trial is testingEffects of a 12-week Strength Training Program in Women With Myotonic Dystrophy Type 1Who this might be right forMyotonic Dystrophy 1 Université de Sherbrooke 12
Testing effectiveness (Phase 2)Active Not RecruitingNCT02326974What this trial is testingT-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCAWho this might be right forHER-2 Positive Breast CancerBreast CancerStage II Breast Cancer+1 more Dana-Farber Cancer Institute 164
Testing effectiveness (Phase 2)WithdrawnNCT03203616What this trial is testingKadcyla In pAtients With bRAin MetastasisWho this might be right forMetastatic HER2-positive Breast Cancer With Brain Metastasis Jules Bordet Institute
Testing effectiveness (Phase 2)Ended earlyNCT03709082What this trial is testingPalbociclib in Estrogen Receptor Positive (ER+) Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast CancerWho this might be right forHER2-positive Breast CancerBreast Cancer Metastatic University of Kansas Medical Center 3
Not applicableLooking for participantsNCT06928818What this trial is testingTrastuzumab Emtansine(T-DM1) After Trastuzumab Deruxtecan(T-DXd) in HER2-Positive Breast Cancer in KoreaWho this might be right forCancer of BreastTrastuzumab EmtansineTrastuzumab Deruxtecan Seoul National University Hospital 100
Testing effectiveness (Phase 2)Study completedNCT04886518What this trial is testingSafety and Efficacy of Pitolisant on Excessive Daytime Sleepiness and Other Non-Muscular Symptoms in Patients With Myotonic Dystrophy Type 1Who this might be right forMyotonic Dystrophy 1Excessive Daytime Sleepiness Harmony Biosciences Management, Inc. 30
Large-scale testing (Phase 3)Active Not RecruitingNCT04457596What this trial is testingT-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD TrialWho this might be right forAnatomic Stage II Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8HER2 Positive Breast Carcinoma+4 more Alliance for Clinical Trials in Oncology 1,056
Testing effectiveness (Phase 2)UnknownNCT04158947What this trial is testingHER2+ Breast Cancer Patients With Active Brain Metastases Treated With Afatinib & T-DM1 vs. T-DM1 AloneWho this might be right forHER2-positive Breast CancerBrain Metastases xuexin he 130